Showing results (281-290 of 756) with videos related to
Sort By:
Pageof 76
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, et al.American Journal of Physiology. Renal Physiology|December 25, 2015
Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?Rubina Novelli, Elena Gagliardini, Barbara Ruggiero, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4Piero Ruggenenti, Giorgio Gentile, Norberto Perico, et al.Journal of the American Society of Nephrology : JASN|May 15, 2010
Sirolimus therapy to halt the progression of ADPKDNorberto Perico, Luca Antiga, Anna Caroli, et al.Panminerva Medica|April 28, 2021
Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortalityGianfranco Alicandro, Carlo La Vecchia, Giuseppe Remuzzi, et al.La Medicina Del Lavoro|December 23, 2021
Excess total mortality in 2021 in Italy was about one third of that observed in 2020Gianfranco Alicandro, Giuseppe Remuzzi, Stefano Centanni, et al.La Medicina Del Lavoro|April 28, 2022
Excess total mortality during the Covid-19 pandemic in Italy: updated estimates indicate persistent excess in recent monthsGianfranco Alicandro, Giuseppe Remuzzi, Stefano Centanni, et al.La Medicina Del Lavoro|June 29, 2022
No excess mortality among working-age Italians during the Omicron wave of Covid-19Gianfranco Alicandro, Giuseppe Remuzzi, Stefano Centanni, et al.Nephron. Clinical Practice|November 12, 2003
Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic modelBorislav D Dimitrov, Piero Ruggenenti, Rumen Stefanov, et al.Journal of the American Society of Nephrology : JASN|November 4, 2006
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trialPiero Ruggenenti, Annalisa Perna, Maria Ganeva, et al.Pageof 76